Radnostix announced multiple material actions: the purchase of the Lara System and Ellexa Explorer assets for $900,000 plus potential milestone and earn-out consideration; a $500,000 5% convertible note financing with Kershner Grosso & Co. convertible at $0.07 per share; and amendments to historic notes that release liens, add conversion features, and extend maturities to 2031. Management positions these steps to expand the company's nuclear medicine technology portfolio while strengthening liquidity and simplifying its capital structure.
Agreement 1: Radnostix Buys Lara System and Ellexa Explorer Assets for $900,000 Plus Milestones
- Agreement type: Asset Purchase Agreement
- Counterparty: Lucerno Dynamics
- Signed / Effective: Jun 25 2026 / Jun 25 2026
- Duration / Termination: N/A
- Reason: Expand nuclear medicine technology portfolio
Agreement 2: Radnostix Raises $500,000 Via 5% Convertible Note at $0.07 Conversion Price
- Agreement type: Convertible Promissory Note
- Counterparty: Kershner Grosso & Co.
- Signed / Effective: Jun 23 2026 / Jun 23 2026
- Duration / Termination: Matures Jun 30 2031
- Reason: Enhance liquidity and support initiatives
Agreement 3: Radnostix Amends Historic Notes: $0.07 Conversion, Forced Conversion at $0.12 VWAP, Maturity to 2031
- Agreement type: Amendments to 2013, 2018, and 2019–2020 promissory notes
- Counterparty: Various related lenders
- Signed / Effective: Jun 30 2026 / Jun 30 2026
- Duration / Termination: Maturity extended to Mar 31 2031
- Reason: Simplify capital structure and improve flexibility
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.